Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ro, Youngouk | - |
dc.contributor.author | Eun, Chang Soo | - |
dc.contributor.author | Kim, Hyun Soo | - |
dc.contributor.author | Kim, Ji Yeoun | - |
dc.contributor.author | Byun, Young Jae | - |
dc.contributor.author | Yoo, Kyo-Sang | - |
dc.contributor.author | Han, Dong Soo | - |
dc.date.accessioned | 2021-07-30T05:28:17Z | - |
dc.date.available | 2021-07-30T05:28:17Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2016-07 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5015 | - |
dc.description.abstract | Background/Aims Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are commonly prescribed for stress ulcer prophylaxis (SUP) in critically ill patients. Several studies have suggested that the use of PPIs is a potential risk factor for Clostridium difficile infection (CDI). We compared the incidences of CDI in the PPI group and H2RA group for SUP in critically ill patients. Methods From August 2005 to July 2012, the incidences of CDI were retrospectively analyzed in patients who were admitted directly to intensive care units and stayed for more than 3 days. SUP-related CDI was defined as a CDI diagnosed during the SUP period. Patient clinical data were analyzed to identify potential risk factors for SUP-related CDI. Results Of the 1,005 patients enrolled (444 patients received PPI and 561 received H2RA), 38 (3.8%) were diagnosed with SUP-related CDI. The incidence of SUP-related CDI was considerably higher in patients who received PPI than in those who received H2RA (6.7% vs 1.8%). PPI use for SUP (odds ratio [OR], 3.3; confidence interval [CI], 1.5 to 7.1; p=0.003) and diabetes mellitus (OR, 2.3; CI, 1.2 to 4.7; p=0.019) were independent risk factors for SUP-related CDI. Conclusions PPI therapy is associated with a higher risk of SUP-related CDI than H2RA therapy in critically ill patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | EDITORIAL OFFICE GUT & LIVER | - |
dc.title | Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Eun, Chang Soo | - |
dc.contributor.affiliatedAuthor | Han, Dong Soo | - |
dc.identifier.doi | 10.5009/gnl15324 | - |
dc.identifier.scopusid | 2-s2.0-84978531974 | - |
dc.identifier.wosid | 000379989900019 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, v.10, no.4, pp.581 - 586 | - |
dc.relation.isPartOf | GUT AND LIVER | - |
dc.citation.title | GUT AND LIVER | - |
dc.citation.volume | 10 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 581 | - |
dc.citation.endPage | 586 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002128657 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | INTENSIVE-CARE-UNIT | - |
dc.subject.keywordPlus | RECEPTOR ANTAGONISTS | - |
dc.subject.keywordPlus | COST-EFFECTIVENESS | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | OBESITY | - |
dc.subject.keywordAuthor | Clostridium difficile | - |
dc.subject.keywordAuthor | Proton pump inhibitor | - |
dc.subject.keywordAuthor | Histamine-2 receptor antagonist | - |
dc.subject.keywordAuthor | Critical care | - |
dc.identifier.url | https://www.gutnliver.org/journal/view.html?doi=10.5009/gnl15324 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.